| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: =98.34%
| Targets |
Neuropeptide; antioxidant; anxiolytic
Emideltide targets neuropeptide systems involved in sleep regulation and stress response. As a neuropeptide, it acts as a sleep-inducing peptide, likely through interactions with specific receptors in the brain. It has antioxidant properties, potentially through modulation of SOD (superoxide dismutase). It also has anxiolytic properties. Its mechanism may involve modulation of neurotransmitter systems and circadian rhythm regulation. |
|---|---|
| ln Vitro |
In vitro, emideltide has antioxidant properties. Its effects on neuronal cells and neurotransmitter systems have been studied. The peptide may modulate oxidative stress and neuroinflammation in cellular models. Its ability to induce sleep and reduce anxiety has been demonstrated in animal studies. However, detailed in vitro activity data is limited.
|
| ln Vivo |
In rabbits, delta-sleep-inducing peptide (DSIP) produces decreased heart and respiratory rate control and increased spindle activity [1]. Delta-sleep-inducing peptide (DSIP; 40-360 μg/kg, i.p.) rapidly labels homogenates at 40 μg/kg malondialdehyde (MDA) concentration and boosts catalase and superoxide dismutase (SOD) activity in the matrix [2]. However, the correct effect was found at 120 μg/kg and 360 μg/kg.
In vivo, emideltide (DSIP) produces decreased heart and respiratory rate and increased spindle activity in rabbits. It induces delta sleep in mammals. It has anxiolytic effects in animal models. Plasma DSIP concentrations are correlated with the human circadian rhythm and are dependent on the initiation of sleep. The peptide may act as a suprachiasmatic programming modulator. |
| Enzyme Assay |
In vitro receptor binding assays for emideltide are not well-established, as its specific receptor has not been definitively identified. Binding studies may use brain membrane preparations and radiolabeled DSIP or related peptides. Functional assays measure effects on neuronal activity in brain slices or cultured neurons. Antioxidant activity is assessed using cell-free or cell-based ROS detection assays.
|
| Cell Assay |
Cellular assays for emideltide use neuronal cell cultures or brain slices. Cells are treated with various concentrations of emideltide. Neuronal activity is assessed by electrophysiological recordings or calcium imaging. Oxidative stress markers are measured using fluorescent dyes. Neurotransmitter release is measured using HPLC or microdialysis.
|
| Animal Protocol |
In vivo animal studies for emideltide utilize rabbits, mice, or other mammals. The peptide is administered via intracerebroventricular (ICV) injection or intravenous infusion. Sleep-wake patterns are monitored by EEG/EMG recordings. Heart and respiratory rates are measured. Anxiety-like behavior is assessed using elevated plus maze or other behavioral tests. Circadian rhythm parameters are measured.
|
| ADME/Pharmacokinetics |
Emideltide has molecular weight of 848.81 g/mol and is a nonapeptide. As a peptide, it has poor oral bioavailability and is typically administered via injection or central routes for research purposes. Pharmacokinetic properties include rapid clearance by peptidases. The peptide's short half-life necessitates frequent dosing or continuous administration in vivo studies. It is stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity of emideltide is not extensively documented. As an endogenous neuropeptide, it is generally considered to have low toxicity. In animal studies, the peptide is well-tolerated at the doses used for sleep and anxiety research. No significant adverse effects have been reported. Standard toxicology studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
This is a nonapeptide found in neurons, peripheral organs, and blood plasma. This neuropeptide primarily induces delta sleep in mammals. In addition to sleep, this peptide has been observed to affect brain electrophysiological activity, neurotransmitter levels in the brain, circadian rhythms and movement patterns, hormone levels, psychological performance, and the activity of neuropharmacological drugs (including their withdrawal reactions).
Emideltide (δ-Sleep Inducing Peptide, DSIP) is a synthetic nonapeptide that induces delta sleep in mammals. It has antioxidant and anxiolytic properties. It decreases heart and respiratory rates and increases spindle activity in rabbits. It is correlated with circadian rhythm regulation. It is available for research purposes only. |
| Molecular Formula |
C35H48N10O15
|
|---|---|
| Molecular Weight |
848.813620000001
|
| Exact Mass |
848.33
|
| Elemental Analysis |
C, 49.53; H, 5.70; N, 16.50; O, 28.27
|
| CAS # |
62568-57-4
|
| PubChem CID |
68816
|
| Sequence |
L-tryptophyl-L-alanyl-glycyl-glycyl-L-alpha-aspartyl-L-alanyl-L-seryl-glycyl-L-glutamic acid;
H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
|
| SequenceShortening |
WAGGDASGE; H-WAGGDASGE-OH
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
1522.7±65.0 °C at 760 mmHg
|
| Flash Point |
874.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
-3.57
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
60
|
| Complexity |
1610
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](NC([C@@H](N)CC1=CNC2=CC=CC=C12)=O)C(NCC(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CO)=O)C)=O)CC(O)=O)=O)=O)=O
|
| InChi Key |
ZRZROXNBKJAOKB-GFVHOAGBSA-N
|
| InChi Code |
InChI=1S/C35H48N10O15/c1-16(41-32(56)20(36)9-18-11-37-21-6-4-3-5-19(18)21)30(54)39-12-25(47)38-13-26(48)44-23(10-29(52)53)34(58)42-17(2)31(55)45-24(15-46)33(57)40-14-27(49)43-22(35(59)60)7-8-28(50)51/h3-6,11,16-17,20,22-24,37,46H,7-10,12-15,36H2,1-2H3,(H,38,47)(H,39,54)(H,40,57)(H,41,56)(H,42,58)(H,43,49)(H,44,48)(H,45,55)(H,50,51)(H,52,53)(H,59,60)/t16-,17-,20-,22-,23-,24-/m0/s1
|
| Chemical Name |
L-tryptophyl-L-alanylglycylglycyl-L-aspartyl-L-alanyl-L-serylglycyl-L-glutamic acid
|
| Synonyms |
δ-Sleep Inducing Peptide;Emideltide; 62568-57-4; DSIP nonapeptide; Emideltide [INN]; DELTA SLEEP-INDUCING PEPTIDE; DSIP nonapeptide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1781 mL | 5.8906 mL | 11.7812 mL | |
| 5 mM | 0.2356 mL | 1.1781 mL | 2.3562 mL | |
| 10 mM | 0.1178 mL | 0.5891 mL | 1.1781 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA